Advanced Medical Isotope Corp. Pitch Deck Teardown

Executive Summary and Technology Overview

Slide 1: Title Slide

The presentation opens with the company name, Advanced Medical Isotope Corporation, and its logo, AMI. The slide identifies Dr. Michael Korenko as the President and Chief Executive Officer. The date is listed as August 1, 2017. Notably, the footer indicates the company is publicly traded on the OTC under the ticker ADMD. The visual includes a graphic of a syringe injecting radioactive particles into a tumor mass, immediately establishing the medical context.

Slide 3: Overview

This slide defines the company's core business: the late-stage development of a brachytherapy device for medical and veterinary cancer applications. It provides a dictionary definition of brachytherapy as the treatment of cancer via radioactive implants (isotopes) placed directly into or next to the treatment area. The slide outlines a three-pronged strategy: leveraging a competent team with national lab partnerships, generating near-term revenue from veterinary clinics, and pursuing FDA approval for human indications. It highlights the 'drug-like' economics of the product but with the 'shorter approval path' of a medical device.

Slide 5: Platform Technology: RadioGel

Slide 5 details the technical specifications of the RadioGel platform. It is described as a next-generation radiopharmaceutical therapeutic device. The delivery vehicle is a hydrogel that is liquid at room temperature but solidifies at body temperature to lock particles in place. The active particle is Yttrium-90 phosphate, an insoluble particle that perfuses within the tumor. Key technical stats include its status as a high-energy beta emitter, a short radiation travel distance to minimize collateral damage, and a 2.7-day half-life, meaning only 5% of radiation remains after 10 days. Visuals show both interstitial and intra-arterial injection methods.

Market Strategy and Revenue Projections

Slide 7: Initial Market: Veterinary Applications

The company identifies the veterinary sector as its entry point. The slide uses a simple three-step process flow: 1) Obtain approval to test, 2) Demonstrate therapies at leading research universities, and 3) Begin sales to private clinics. This suggests a strategy of building clinical credibility through academic partnerships before moving into the commercial private clinic market.

Slide 9: Veterinary Market Opportunity

This slide quantifies the veterinary opportunity. It cites that there are 78 million dogs and 86 million cats in the U.S., with cancer being the leading cause of death for 32% of cats and 50% of dogs over age 10. The revenue model assumes a $5,000 therapy cost. Treating 10% of these cancers is projected to generate $40 million in annual revenue. The slide sets a target for revenue streams to begin by January 2018 or earlier.

Slide 11: Human Skin Cancer Market Projections

Shifting to human medicine, the deck focuses on Basal Cell and Squamous Cell skin cancers. It notes that one out of every three new cancers is skin cancer, with 5.4 million cases annually in the U.S. affecting 3.3 million people. Using the same 10% penetration assumption and a $5,000 price point, the company projects $1.5 billion in annual revenues. It suggests international licensing revenue could begin in early 2018.

Slide 13: Medical Sector Growth Strategy

Slide 13 provides a roadmap for human medical indications. The growth is depicted as a series of 'quantum steps' moving from the simplest application to the most complex. The sequence is: Skin Cancer, followed by Lymph Nodes, and finally Liver/Pancreas. This indicates a phased regulatory and clinical trial approach, starting with accessible surface tumors before moving to internal organs.

Governance and Intellectual Property

Slide 15: Intellectual Property Protection

The company emphasizes its defensive moat here. It has retained an IP attorney and secured rights to eight patents through a sublicensing agreement with Battelle. The slide mentions trademark protection in 17 countries and proprietary IP covering production procedures, test data, and product development (specifically resorption time and imaging). This slide is intended to reassure investors that the technology is protected from generic competition.

Slide 17: Medical & Scientific Advisory Boards

Leadership credibility is bolstered by three chairpersons: Dr. Barry D. Pressman (Medical Advisory Board), Dr. Alan E. Waltar (Scientific Advisory Board), and Dr. Alice Villalobos (Veterinary Medicine Advisory Board). Three additional members are listed: Dr. Albert S. DeNittis, Dr. Darrell Fisher, and Dr. Howard Sandler. The inclusion of a dedicated veterinary chair reinforces the importance of the pet-health revenue stream.

Slide 19: Highlights

The final slide summarizes the investment thesis. It reiterates the early 2018 revenue targets for IsoPet and international licensing. It mentions the 'world-class' advisory boards and partnerships with national labs. Critically, it states a plan to 'uplist to senior exchange (NASDAQ or NYSE MKT),' which is a common goal for OTC-traded companies seeking higher liquidity and institutional investment. It concludes by highlighting the attractive drug economics and extensive IP protections.

What Works Well

The deck clearly explains a complex scientific product (RadioGel) in terms that a generalist investor can understand, specifically the 'liquid to solid' transition of the hydrogel. The dual-track strategy—using the veterinary market for quick cash flow while pursuing the larger human medical market—is a logical way to mitigate the long timelines and high costs associated with FDA human clinical trials. The use of specific isotope data (2.7-day half-life) and clear pricing assumptions ($5,000 per treatment) provides a concrete basis for their revenue projections.

What Is Missing

The most significant omission is a detailed financial history and a specific 'ask.' While the deck mentions being an OTC company, it does not provide current cash on hand, burn rate, or the amount of capital they are seeking to raise in this specific round. There is no slide dedicated to unit economics beyond the top-line price point; information on the cost of goods sold (COGS) or manufacturing margins for the isotopes and hydrogel is absent. Furthermore, there is no competitive landscape slide. While the technology is proprietary, other forms of brachytherapy and traditional radiation treatments exist, and the deck fails to explicitly compare RadioGel's efficacy or cost against these incumbents.

Founder Takeaways

Phased Market Entry: Founders in highly regulated industries (like MedTech or Biotech) should emulate AMI's strategy of identifying a 'path of least resistance' for early revenue. Using the veterinary market to prove the technology and generate cash while the human clinical trials progress is a sophisticated way to reduce investor risk. Clear Technical Visuals: The use of simple diagrams to show how the product is administered (Slide 5) is much more effective than dense text. Advisory Board Segmentation: If your product spans multiple industries, segmenting your advisory board (as seen on Slide 17) shows that you have deep expertise in every vertical you intend to enter, rather than just a general medical board.